| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/06/2005 | WO2005000314A1 Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
| 01/06/2005 | WO2005000304A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | WO2005000299A1 Compositions comprising balaglitazone and further antidiabetic compounds |
| 01/06/2005 | WO2005000297A1 Treatment of migraine accompanied by nausea |
| 01/06/2005 | WO2005000294A1 Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| 01/06/2005 | WO2005000292A1 Cancer treatment with epothilones |
| 01/06/2005 | WO2005000287A1 External preparation for athlete's foot treatment |
| 01/06/2005 | WO2005000285A2 METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS |
| 01/06/2005 | WO2005000284A2 Diaryl ureas for diseases mediated by pdgfr |
| 01/06/2005 | WO2005000283A2 A method of treating degenerative disc disease |
| 01/06/2005 | WO2005000270A2 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 01/06/2005 | WO2005000224A2 Novel dermatological composition |
| 01/06/2005 | WO2005000216A2 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| 01/06/2005 | WO2005000211A2 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes |
| 01/06/2005 | WO2005000210A2 Synthesis of high molecular weight iron-saccharidic complexes |
| 01/06/2005 | WO2005000208A2 Combination therapy for the treatment of neoplasms |
| 01/06/2005 | WO2005000040A1 Infant formula |
| 01/06/2005 | WO2004103336A3 Drug delivery system |
| 01/06/2005 | WO2004098580A3 A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| 01/06/2005 | WO2004089417A9 Drug-enclosing multilayer structure particulate and process for producing the same |
| 01/06/2005 | WO2004089396A3 Anti-fungal peptidomimetics |
| 01/06/2005 | WO2003103643A8 Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor |
| 01/06/2005 | WO2003050255A3 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer |
| 01/06/2005 | WO2003041654A3 Anti-estrogen and immune modulator combinations for treating breast cancer |
| 01/06/2005 | WO2003032912A9 Treatment of cns disorders using cns target modulators |
| 01/06/2005 | US20050004663 Heparin barrier coating for controlled drug release |
| 01/06/2005 | US20050004428 Cardiac disease treatment and device |
| 01/06/2005 | US20050004226 Compositions and methods for amelioration of human female sexual dysfunction |
| 01/06/2005 | US20050004225 Oxidoreductase inhibitors and methods of screening and using thereof |
| 01/06/2005 | US20050004222 Methods for prevention and treatment of gastrointestinal disorders |
| 01/06/2005 | US20050004199 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 01/06/2005 | US20050004194 Use of organic compounds |
| 01/06/2005 | US20050004193 Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases |
| 01/06/2005 | US20050004171 Increasing blood absorption of proton pump inhibitor; adjusting stomach gastric fluid pH with buffering agent to inhibit acid degradation |
| 01/06/2005 | US20050004155 Use of methylnaltrexone to treat irritable bowel syndrome |
| 01/06/2005 | US20050004145 KW-3902 (8-(3-noradamantyl)-1,3-dipropylxanthine) as adenosine A1 receptor antagonist combined with at least one other diuretic |
| 01/06/2005 | US20050004144 Broad spectrum, long lasting, nontoxic synthetic immunostimulatory agents; inducing interferon production; inosine monophosphate dehydrogenase (IMPDH); cancer, autoimmune diseases |
| 01/06/2005 | US20050004142 furo(2,3-d)pyrimidine and thieno(2,3-d)pyrimidine compounds for treating cancer and hyperproliferative diseases; receptor tyrosine kinase inhibitors |
| 01/06/2005 | US20050004124 Synergistic mixture; antidiabetic agents; antiischemic agents |
| 01/06/2005 | US20050004110 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 01/06/2005 | US20050004108 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degenaration |
| 01/06/2005 | US20050004106 Therapy for drug resistant disease; anxiolytic agents; psychological disorders |
| 01/06/2005 | US20050004090 Novel estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/06/2005 | US20050004088 Hormonal contraceptive product |
| 01/06/2005 | US20050004084 Aspirin-containing trasdermal pharmaceutical composition for the treatment of calcification |
| 01/06/2005 | US20050004081 Pharmaceutical combinations for the treatment of cancer |
| 01/06/2005 | US20050004068 Modulation of tor |
| 01/06/2005 | US20050004061 Immunostimulatory nucleic acid molecules |
| 01/06/2005 | US20050004056 Ptp10d, tec protein tyrosine kinase and edtp homologous proteins involved in the regulation of energy homeostasis |
| 01/06/2005 | US20050004055 Synergistic process; electrical stimulation; administering hyaluronidase |
| 01/06/2005 | US20050004039 Selective analgesic agents |
| 01/06/2005 | US20050004030 Degradation spores; infection therapy |
| 01/06/2005 | US20050004027 Administering a compound which blocks endothelial growth factor |
| 01/06/2005 | US20050004018 Use of antitumoral compound in cancer therapy |
| 01/06/2005 | US20050004015 Novel haemopoietin receptor and genetic sequences encoding same |
| 01/06/2005 | US20050003492 Novel polypeptide |
| 01/06/2005 | US20050003457 Immunoglobulin which binds osteoclastogenesis inhibitory factor binding molecules (OBM)) and prevents bone resorption for use in treatment and prevention of bone disorders |
| 01/06/2005 | US20050003453 G-CSF analog compositions and methods |
| 01/06/2005 | US20050003451 Immunoglobulin for use in diagnosis, prevention and treatment of infection, autoimmune, inflammatory and cell proliferative diseases; immunotherapy |
| 01/06/2005 | US20050003446 Peptide sequences for use in identification of modulators for use in treatment and prevention of inflammatory, cell proliferative, arteriosclerotic and skin disorders |
| 01/06/2005 | US20050003368 Cancer monitoring and therapeutics |
| 01/06/2005 | US20050003353 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/06/2005 | US20050003352 Comprises recombinant mitochondrial transport protein for diagnosis, prevention and treatment of alzheimer's, diabetes, parkinson's, huntington's, cancers |
| 01/06/2005 | US20050003024 Regulation of mammalian hair growth |
| 01/06/2005 | US20050003023 Topical composition for the treatment of psoriasis and related skin disorders |
| 01/06/2005 | US20050003021 Bowel cleansing agent |
| 01/06/2005 | US20050003009 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
| 01/06/2005 | US20050003003 Modulation of release from dry powder formulations |
| 01/06/2005 | US20050002986 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/06/2005 | US20050002985 Device with recessed tracks for forming a cellular network |
| 01/06/2005 | US20050002979 Topical urea application; protecting and repairing skin |
| 01/06/2005 | US20050002938 To screen for inhibitors of cell growth and to develop small molecule therapeutics for treating cancers |
| 01/06/2005 | US20050002937 Anti-IL-12 antibodies, compositions, methods and uses |
| 01/06/2005 | US20050002936 Methods and compositions useful for inhibition of angiogenesis |
| 01/06/2005 | US20050002933 Proliferation and/or differentiation of stem and progenitor cells from embryo or adult |
| 01/06/2005 | US20050002928 Treatment with anti-ErbB2 antibodies |
| 01/06/2005 | US20050002918 Selective treatment of IL-13 expressing tumors |
| 01/06/2005 | US20050002901 Compositions and methods for treating coronavirus infection and SARS |
| 01/06/2005 | US20050002900 Inhibiting estradiol production in human adipocytes using interferon gamma and/or tumor necrosis factor antagonist and/or interleukin-1 antagonist; reducing side effects |
| 01/06/2005 | US20050002899 Serum and mitogen free; inducing tumor cells to enter proliferative cycle phase |
| 01/06/2005 | US20050002896 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/06/2005 | CA2531019A1 Preventive/remedy for urinary disturbance |
| 01/06/2005 | CA2530668A1 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 01/06/2005 | CA2530381A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic or antidepressant agent, and use thereof for the preparationof a medicament that prevents the adverse effects of psychotropic drugs |
| 01/06/2005 | CA2530311A1 Cancer treatment with epothilones |
| 01/06/2005 | CA2530228A1 Compositions comprising balaglitazone and further antidiabetic compounds |
| 01/06/2005 | CA2530170A1 Infant formula |
| 01/06/2005 | CA2529151A1 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 01/06/2005 | CA2528634A1 Treatment of migraine accompanied by nausea |
| 01/06/2005 | CA2528353A1 Compositions and methods for treatment of rosacea |
| 01/06/2005 | CA2527689A1 Recombinant anti-cd30 antibodies and uses thereof |
| 01/06/2005 | CA2526971A1 Novel dermatological composition |
| 01/06/2005 | CA2526150A1 Treatment of humans with colloidal silver composition |
| 01/06/2005 | CA2526085A1 Treatment with anti-vegf antibodies |
| 01/06/2005 | CA2525928A1 A method of treating degenerative disc disease |
| 01/06/2005 | CA2525788A1 Anti-adhesion composites and methods of use thereof |
| 01/06/2005 | CA2521662A1 Methods and compositions for enhancing immune response |
| 01/05/2005 | EP1493750A2 HCV regulated proteins |
| 01/05/2005 | EP1493448A1 Medicinal composition comprising acat inhibitor and insuline resistance improving agent |
| 01/05/2005 | EP1493445A1 Inhibition of stress-induced ligand-dependent EGFR activation |